- Home
- FTHM vs MDCX Comparison
FTHM vs MDCX Comparison
Compare FTHM & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FTHM | MDCX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 10.9M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FTHM | MDCX |
|---|---|---|
| Price | $0.17 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $203.75 |
| AVG Volume (30 Days) | ★ 516.4K | 65.7K |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,477,000.00 | N/A |
| Revenue This Year | $9.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.17 | $2.12 |
| 52 Week High | $1.52 | $127.50 |
Technical Indicators
Market Signals| Indicator | FTHM | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 25.18 | 16.78 |
| Support Level | N/A | N/A |
| Resistance Level | $0.92 | $8.55 |
| Average True Range (ATR) | 0.02 | 0.35 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 18.10 | 3.23 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.